CN1698636A - Mixing method of antiparasitic preparation for animals - Google Patents
Mixing method of antiparasitic preparation for animals Download PDFInfo
- Publication number
- CN1698636A CN1698636A CN 200410037954 CN200410037954A CN1698636A CN 1698636 A CN1698636 A CN 1698636A CN 200410037954 CN200410037954 CN 200410037954 CN 200410037954 A CN200410037954 A CN 200410037954A CN 1698636 A CN1698636 A CN 1698636A
- Authority
- CN
- China
- Prior art keywords
- preparation
- albendazole
- oxygen
- avermectins medicine
- dosage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 239
- 238000000034 method Methods 0.000 title claims abstract description 78
- 241001465754 Metazoa Species 0.000 title claims abstract description 51
- 230000002141 anti-parasite Effects 0.000 title claims abstract description 17
- 239000003096 antiparasitic agent Substances 0.000 title claims abstract description 9
- 238000002156 mixing Methods 0.000 title abstract description 5
- 239000003814 drug Substances 0.000 claims abstract description 104
- 239000005660 Abamectin Substances 0.000 claims abstract description 89
- 239000007788 liquid Substances 0.000 claims abstract description 70
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 56
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims abstract description 49
- LAZPBGZRMVRFKY-HNCPQSOCSA-N Levamisole hydrochloride Chemical compound Cl.C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 LAZPBGZRMVRFKY-HNCPQSOCSA-N 0.000 claims abstract description 44
- 239000000725 suspension Substances 0.000 claims abstract description 43
- 239000007787 solid Substances 0.000 claims abstract description 37
- 239000000243 solution Substances 0.000 claims abstract description 37
- 238000002347 injection Methods 0.000 claims abstract description 27
- 239000007924 injection Substances 0.000 claims abstract description 27
- 229960002669 albendazole Drugs 0.000 claims description 84
- HXHWSAZORRCQMX-UHFFFAOYSA-N albendazole Chemical compound CCCSC1=CC=C2NC(NC(=O)OC)=NC2=C1 HXHWSAZORRCQMX-UHFFFAOYSA-N 0.000 claims description 84
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 60
- VXTGHWHFYNYFFV-LJQANCHMSA-N (R)-albendazole S-oxide Chemical compound CCC[S@@](=O)C1=CC=C2NC(NC(=O)OC)=NC2=C1 VXTGHWHFYNYFFV-LJQANCHMSA-N 0.000 claims description 48
- 229950010102 albendazole oxide Drugs 0.000 claims description 48
- 239000000203 mixture Substances 0.000 claims description 48
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 claims description 46
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 claims description 46
- VXTGHWHFYNYFFV-UHFFFAOYSA-N albendazole S-oxide Chemical compound CCCS(=O)C1=CC=C2NC(NC(=O)OC)=NC2=C1 VXTGHWHFYNYFFV-UHFFFAOYSA-N 0.000 claims description 46
- 229950010075 albendazole sulfoxide Drugs 0.000 claims description 46
- 229960002418 ivermectin Drugs 0.000 claims description 46
- 229960003734 levamisole hydrochloride Drugs 0.000 claims description 43
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 40
- 229910052760 oxygen Inorganic materials 0.000 claims description 40
- 239000001301 oxygen Substances 0.000 claims description 40
- RDAYADGMQHPARB-UHFFFAOYSA-N [O].Cl Chemical compound [O].Cl RDAYADGMQHPARB-UHFFFAOYSA-N 0.000 claims description 39
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 36
- 208000030852 Parasitic disease Diseases 0.000 claims description 31
- -1 phosphate ester Chemical class 0.000 claims description 27
- 235000011187 glycerol Nutrition 0.000 claims description 25
- 238000010254 subcutaneous injection Methods 0.000 claims description 24
- 239000007929 subcutaneous injection Substances 0.000 claims description 24
- 229920002472 Starch Polymers 0.000 claims description 22
- 239000008107 starch Substances 0.000 claims description 22
- 235000019698 starch Nutrition 0.000 claims description 22
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 21
- 241000283690 Bos taurus Species 0.000 claims description 20
- 241001494479 Pecora Species 0.000 claims description 20
- 239000012876 carrier material Substances 0.000 claims description 20
- 239000003795 chemical substances by application Substances 0.000 claims description 20
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 claims description 20
- 230000037396 body weight Effects 0.000 claims description 14
- 238000003304 gavage Methods 0.000 claims description 13
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 13
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 13
- 239000002202 Polyethylene glycol Substances 0.000 claims description 12
- 238000001647 drug administration Methods 0.000 claims description 12
- 229920001223 polyethylene glycol Polymers 0.000 claims description 12
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 12
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 10
- 230000036592 analgesia Effects 0.000 claims description 10
- 229960004926 chlorobutanol Drugs 0.000 claims description 10
- 239000008215 water for injection Substances 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 9
- 239000007900 aqueous suspension Substances 0.000 claims description 8
- 238000009833 condensation Methods 0.000 claims description 8
- 230000005494 condensation Effects 0.000 claims description 8
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 8
- 239000002612 dispersion medium Substances 0.000 claims description 8
- 239000000194 fatty acid Substances 0.000 claims description 8
- 229930195729 fatty acid Natural products 0.000 claims description 8
- 238000009472 formulation Methods 0.000 claims description 8
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 claims description 8
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 7
- IQXJCCZJOIKIAD-UHFFFAOYSA-N 1-(2-methoxyethoxy)hexadecane Chemical compound CCCCCCCCCCCCCCCCOCCOC IQXJCCZJOIKIAD-UHFFFAOYSA-N 0.000 claims description 6
- 239000003963 antioxidant agent Substances 0.000 claims description 6
- 230000003078 antioxidant effect Effects 0.000 claims description 6
- 229950009789 cetomacrogol 1000 Drugs 0.000 claims description 6
- WFKAJVHLWXSISD-UHFFFAOYSA-N isobutyramide Chemical compound CC(C)C(N)=O WFKAJVHLWXSISD-UHFFFAOYSA-N 0.000 claims description 6
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims description 6
- NOYRGONWBIVLEL-SNAWJCMRSA-N (e)-1,1-dimethoxybut-2-ene Chemical compound COC(OC)\C=C\C NOYRGONWBIVLEL-SNAWJCMRSA-N 0.000 claims description 5
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 claims description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 4
- 241001597008 Nomeidae Species 0.000 claims description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 4
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 claims description 4
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 claims description 4
- 229920003086 cellulose ether Polymers 0.000 claims description 4
- 150000002170 ethers Chemical class 0.000 claims description 4
- 239000004530 micro-emulsion Substances 0.000 claims description 4
- YZBLFMPOMVTDJY-CBYMMZEQSA-N moxidectin Chemical compound O1[C@H](C(\C)=C\C(C)C)[C@@H](C)C(=N/OC)\C[C@@]11O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 YZBLFMPOMVTDJY-CBYMMZEQSA-N 0.000 claims description 4
- 229960004816 moxidectin Drugs 0.000 claims description 4
- 229920001983 poloxamer Polymers 0.000 claims description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 4
- 239000000600 sorbitol Substances 0.000 claims description 4
- 239000000375 suspending agent Substances 0.000 claims description 4
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims description 4
- 229920001285 xanthan gum Polymers 0.000 claims description 4
- 239000000230 xanthan gum Substances 0.000 claims description 4
- 235000010493 xanthan gum Nutrition 0.000 claims description 4
- 229940082509 xanthan gum Drugs 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 3
- 229960002903 benzyl benzoate Drugs 0.000 claims description 3
- 239000004359 castor oil Substances 0.000 claims description 3
- 235000019438 castor oil Nutrition 0.000 claims description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 3
- 235000013773 glyceryl triacetate Nutrition 0.000 claims description 3
- 229960002622 triacetin Drugs 0.000 claims description 3
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical class CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 claims description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 2
- RNMDNPCBIKJCQP-UHFFFAOYSA-N 5-nonyl-7-oxabicyclo[4.1.0]hepta-1,3,5-trien-2-ol Chemical compound C(CCCCCCCC)C1=C2C(=C(C=C1)O)O2 RNMDNPCBIKJCQP-UHFFFAOYSA-N 0.000 claims description 2
- IBSREHMXUMOFBB-JFUDTMANSA-N 5u8924t11h Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C(C)C)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 IBSREHMXUMOFBB-JFUDTMANSA-N 0.000 claims description 2
- 229930192734 Avilamycin Natural products 0.000 claims description 2
- 239000004190 Avilamycin Substances 0.000 claims description 2
- 229920000858 Cyclodextrin Polymers 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 claims description 2
- 239000005894 Emamectin Substances 0.000 claims description 2
- 229920001732 Lignosulfonate Polymers 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 claims description 2
- PPWHTZKZQNXVAE-UHFFFAOYSA-N Tetracaine hydrochloride Chemical compound Cl.CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 PPWHTZKZQNXVAE-UHFFFAOYSA-N 0.000 claims description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 2
- XIRGHRXBGGPPKY-OTPQUNEMSA-N [(2r,3s,4r,6s)-6-[(2'r,3's,3ar,4r,4'r,6s,7ar)-6-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4s,5s,6s)-6-[(2r,3as,3'ar,6'r,7r,7's,7ar,7'ar)-7'-acetyl-7'-hydroxy-6'-methyl-7-(2-methylpropanoyloxy)spiro[4,6,7,7a-tetrahydro-3ah-[1,3]dioxolo[4,5-c]pyran-2,4'-6,7a-dihydro-3ah- Chemical compound O([C@H]1[C@H](O)C[C@@H](O[C@@H]1C)O[C@H]1[C@H](O)CC2(O[C@]3(C)C[C@@H](O[C@H](C)[C@H]3O2)O[C@H]2[C@@H](OC)[C@@H](C)O[C@H]([C@@H]2O)O[C@H]2[C@H](O)[C@H](OC)[C@H](OC3[C@@H]([C@@H]4O[C@]5(O[C@H]4CO3)[C@@H]3OCO[C@H]3[C@@](O)([C@@H](C)O5)C(C)=O)OC(=O)C(C)C)O[C@@H]2COC)O[C@@H]1C)C(=O)C1=C(C)C(Cl)=C(O)C(Cl)=C1OC XIRGHRXBGGPPKY-OTPQUNEMSA-N 0.000 claims description 2
- 229950008167 abamectin Drugs 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 229960005185 avilamycin Drugs 0.000 claims description 2
- 235000019379 avilamycin Nutrition 0.000 claims description 2
- GTCAXTIRRLKXRU-UHFFFAOYSA-N carbamic acid methyl ester Natural products COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 claims description 2
- 150000001720 carbohydrates Chemical class 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 2
- 125000002091 cationic group Chemical group 0.000 claims description 2
- 238000007334 copolymerization reaction Methods 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- QLFZZSKTJWDQOS-YDBLARSUSA-N doramectin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C3CCCCC3)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C QLFZZSKTJWDQOS-YDBLARSUSA-N 0.000 claims description 2
- 229960003997 doramectin Drugs 0.000 claims description 2
- CXEGAUYXQAKHKJ-NSBHKLITSA-N emamectin B1a Chemical compound C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](NC)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 CXEGAUYXQAKHKJ-NSBHKLITSA-N 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- WPNHOHPRXXCPRA-TVXIRPTOSA-N eprinomectin Chemical compound O1[C@@H](C)[C@@H](NC(C)=O)[C@H](OC)C[C@@H]1O[C@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C(C)C)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C\C=C/[C@@H]2C)\C)O[C@H]1C WPNHOHPRXXCPRA-TVXIRPTOSA-N 0.000 claims description 2
- 229960002346 eprinomectin Drugs 0.000 claims description 2
- ZOOODBUHSVUZEM-UHFFFAOYSA-N ethoxymethanedithioic acid Chemical compound CCOC(S)=S ZOOODBUHSVUZEM-UHFFFAOYSA-N 0.000 claims description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 claims description 2
- 229940093471 ethyl oleate Drugs 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 150000002191 fatty alcohols Chemical class 0.000 claims description 2
- 239000001087 glyceryl triacetate Substances 0.000 claims description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 2
- 239000002563 ionic surfactant Substances 0.000 claims description 2
- 229960004393 lidocaine hydrochloride Drugs 0.000 claims description 2
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 claims description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 claims description 2
- 229920002401 polyacrylamide Polymers 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 229920000136 polysorbate Polymers 0.000 claims description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 2
- 229960001309 procaine hydrochloride Drugs 0.000 claims description 2
- 235000010388 propyl gallate Nutrition 0.000 claims description 2
- 239000000473 propyl gallate Substances 0.000 claims description 2
- 229940075579 propyl gallate Drugs 0.000 claims description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 claims description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 150000005846 sugar alcohols Chemical class 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 229960002494 tetracaine hydrochloride Drugs 0.000 claims description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 2
- 239000008158 vegetable oil Substances 0.000 claims description 2
- 239000012991 xanthate Substances 0.000 claims description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 10
- BEZZFPOZAYTVHN-UHFFFAOYSA-N oxfendazole Chemical compound C=1C=C2NC(NC(=O)OC)=NC2=CC=1S(=O)C1=CC=CC=C1 BEZZFPOZAYTVHN-UHFFFAOYSA-N 0.000 abstract description 2
- 229960004454 oxfendazole Drugs 0.000 abstract description 2
- 241001136249 Agriotes lineatus Species 0.000 abstract 2
- RRZXIRBKKLTSOM-XPNPUAGNSA-N avermectin B1a Chemical compound C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 RRZXIRBKKLTSOM-XPNPUAGNSA-N 0.000 abstract 1
- 239000000843 powder Substances 0.000 description 24
- 239000003826 tablet Substances 0.000 description 20
- 239000005645 nematicide Substances 0.000 description 14
- 244000045947 parasite Species 0.000 description 10
- 230000000507 anthelmentic effect Effects 0.000 description 8
- 206010059866 Drug resistance Diseases 0.000 description 7
- 238000013329 compounding Methods 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 238000011049 filling Methods 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000000214 mouth Anatomy 0.000 description 4
- 241000282898 Sus scrofa Species 0.000 description 3
- 229960001614 levamisole Drugs 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000243976 Haemonchus Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000921 anthelmintic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ZWIPGARCRSFMHK-UHFFFAOYSA-N benzene;1h-imidazole Chemical class C1=CNC=N1.C1=CC=CC=C1 ZWIPGARCRSFMHK-UHFFFAOYSA-N 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 244000078703 ectoparasite Species 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000000749 insecticidal effect Effects 0.000 description 1
- 229960003439 mebendazole Drugs 0.000 description 1
- BAXLBXFAUKGCDY-UHFFFAOYSA-N mebendazole Chemical compound [CH]1C2=NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CC=C1 BAXLBXFAUKGCDY-UHFFFAOYSA-N 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a mixing method of antiparasitic preparation for animals wherein the preparation comprises avermectin deworming medicament, oxfendazole hydrochloride and levamisol hydrochloride, the preparation is in the state of solid or liquid. The application consists of mixing two or more antiparasitic preparations, preparing solution or suspension solution by charging water or not, then administrating orally or through injection. The mixed preparation can be used for treating various wireworms, in particular drug tolerant wireworms.
Description
Technical field
The invention describes the method for using with of veterinary antiparasitic preparation, preparation is made up of Avermectins anthelmintic, hydrochloric acid oxygen Albendazole and levamisole hydrochloride, and preparation is solid state or liquid condition.Two kinds of solid preparations that will contain two or more different anti-parasite medicines during use mix, and convert water and are prepared into solution or suspension, oral administration or drug administration by injection; Also the Avermectins anthelmintic can be prepared into liquid preparation, hydrochloric acid oxygen Albendazole is made solid preparation (also can add levamisole hydrochloride), during use, both be mixed, be prepared into liquid, oral administration or drug administration by injection; Also the Avermectins anthelmintic drug can be prepared into dispersible tablet of water or powder, hydrochloric acid oxygen Albendazole is prepared into tablet or powder, during use, by a certain percentage with both together with water dissolution or dispersion, be prepared into liquid, oral administration.Also Avermectins anthelmintic and levamisole hydrochloride can be prepared into solid preparation, the Albendazole is prepared into liquid preparation with hydrochloric acid oxygen, during use, both is mixed oral administration or drug administration by injection.
Background technology
1, the Avermectins anthelmintic comprises: avilamycin abamectin, ivermectin ivermectin, 4"-Deoxy-4"-epi-methylaminoavermectin B1 emamectin, Ai Purui rhzomorph eprinomectin, road draw rhzomorph doramectin, moxidectin moxidectin.They have good anthelmintic action to extensively parasitizing intravital nematicide of animal and epizoa, from the beginning of the eighties has been the choice drug that people are used to prevent and treat animal parasitic nematode disease and ectoparasite disease since the listing always, therefore, in recent years with regard to nematicide, such medicine has been produced drug resistance in various degree, on the bigger Australia of dosage and medicine frequency, New Zealand, South America and other places, parasitize cattle, intravital some nematicide of sheep (haemonchus, oersted nematicide etc.) has generally produced drug resistance to this type of medicine.
2, benzimidazole medicine such as albendazole, fragrant benzene imidazoles, mebendazole etc., be at the beginning of 70 listing be used for vermifugal anti-parasite medicine, they have the effect of well killing to parasitizing the intravital multiple nematicide of animal, the same with the Avermectins anthelmintic, be the choice drug that people are used to kill nematicide always.Therefore, this medicine has worldwide produced stronger drug resistance at present, is 3～10mg/kgb.w. from the beginning dosage, now brought up to 10～30mg/kgb.w., and its effect is still undesirable.The oxidation product albendazole sulfoxide of albendazole claims the oxygen Albendazole again, and its water solublity significantly improves, and especially the water solublity of its hydrochlorate or 1, the dissolubility in the 2-propylene glycol is higher can reach more than 20%.Albendazole water solublity and poor, about about 1ppm, so its micronized degree has a significant impact its absorption and bioavailability in animal body.Generally speaking, oral albendazole nearly about 40% is not absorbed and used.Experiment shows, replaces albendazole with the hydrochloric acid oxygen Albendazole of good water solubility, is used for the animal anthelmintic, can reduce dosage significantly, about about one times.
3, levamisole is a tetramisole class medicine, be mainly used in and kill intravital some nematicide of animal, owing to worldwide used more than 40 year, therefore, nematicide in its insecticidal spectrum has produced drug resistance in various degree to levamisole, uses seldom in recent years.
4, experiment shows seldom have a certain nematicide simultaneously above three class medicines all to be produced drug resistance, because the anthelmintic of above three class medicines mechanism is different fully.Prove through clinical experiment, by above three kinds of compound preparations that medicine is formed, to produce single chemical sproof nematicide to kill action effect remarkable, this is confirmed in Australian experiment fully.
5, based on above problem, the present invention is with Avermectins medicine, hydrochloric acid oxygen Albendazole and levamisole hydrochloride, combination in certain proportion, be prepared into the specific preparation that is suitable for using with, be used for the control of animal drug resistance nematicide, and said preparation has the effect of killing epizoa, distoma hepaticum and part cestode simultaneously.Generally speaking, animal often infects parasites such as multiple nematicide, distoma hepaticum and cestode simultaneously.Therefore, use this preparation, adopt the method for using with, a drug can reach and kill multiple parasitic purpose, has reduced medication number of times and drug cost, has made things convenient for user, and can effectively control the drug resistance nematicide, reaches the pathogenetic purpose of control parasite.
6, another outstanding feature of the present invention is: different anti-parasite medicines are made the dispersible or water-soluble solid preparation (as tablet or granule) of water, how much press the number of animals raised during use, quantitatively get solid preparation, water disperses or dissolves, use drencher oral administration or drug administration by injection afterwards, use like this, very convenient, tablet dispensing than ordinary straight interface clothes is convenient, and the number of animals raised is big more, be suitable for using this method administration more.
Summary of the invention
Use method 1 with: the solid preparation that will contain Avermectins medicine mixes when in use with the solid preparation that contains oxygen Albendazole or hydrochloric acid oxygen Albendazole, convert water or water for injection or other liquid dispersion medium and be prepared into solution or molten suspension or suspension, be used for the animal parasitosis control, injection or oral administration, during drug administration by injection, dosage is: oxygen Albendazole or hydrochloric acid oxygen Albendazole 2.5～30mg/kg b.w.; Avermectins medicine 0.2～2mg/kg b.w.; During oral administration, dosage is: oxygen Albendazole or hydrochloric acid oxygen Albendazole 5～30mg/kg b.w.; Avermectins medicine 0.1～0.7mg/kg b.w..
Use method 2 with: the liquid preparation that will contain Avermectins medicine mixes when in use with the liquid preparation that contains oxygen Albendazole or hydrochloric acid oxygen Albendazole, be prepared into solution or molten suspension or suspension, be used for the animal parasitosis control, injection or oral administration, during drug administration by injection, dosage is: oxygen Albendazole or hydrochloric acid oxygen Albendazole 2.5～30mg/kg b.w.; Avermectins medicine 0.2～2mg/kg b.w.; During oral administration, dosage is: oxygen Albendazole or hydrochloric acid oxygen Albendazole 5～30mg/kg b.w.; Avermectins medicine 0.1～0.7mg/kg b.w..
Use method 3 with: the liquid preparation that will contain Avermectins medicine mixes when in use with the solid preparation that contains oxygen Albendazole or hydrochloric acid oxygen Albendazole, be prepared into solution or molten suspension or suspension, be used for the animal parasitosis control, injection or oral administration, during drug administration by injection, dosage is: oxygen Albendazole or hydrochloric acid oxygen Albendazole 2.5～30mg/kg b.w.; Avermectins medicine 0.2～2mg/kg b.w.; During oral administration, dosage is: oxygen Albendazole or hydrochloric acid oxygen Albendazole 5～30mg/kg b.w.; Avermectins medicine 0.1～0.7mg/kg b.w..
Use method 4 with: the solid preparation that will contain Avermectins medicine mixes when in use with the liquid preparation that contains oxygen Albendazole or hydrochloric acid oxygen Albendazole, be prepared into solution or molten suspension or suspension, be used for the animal parasitosis control, injection or oral administration, during drug administration by injection, dosage is: oxygen Albendazole or hydrochloric acid oxygen Albendazole 2.5～30mg/kg b.w.; Avermectins medicine 0.2～2mg/kg b.w.; During oral administration, dosage is: oxygen Albendazole or hydrochloric acid oxygen Albendazole 5～30mg/kg b.w.; Avermectins medicine 0.1～0.7mg/kg b.w..
Use with in the method at above-described 4 kinds, also can add the levamisole hydrochloride of 20～70% (W/W) in the described solid preparation that contains Avermectins medicine, or in containing the liquid preparation of Avermectins medicine, add the levamisole hydrochloride of 5～20% (W/V); Or in the solid preparation that contains the oxygen Albendazole, add the levamisole hydrochloride of 20～60% (W/W), or in the liquid preparation that contains the oxygen Albendazole, add the levamisole hydrochloride of 5～20% (W/V); When being used for the animal parasitosis control, the levamisole hydrochloride using dosage is 5～15mg/kg b.w..
Use with in the method at above-described 4 kinds, (1), the described solid preparation that contains oxygen Albendazole or hydrochloric acid oxygen Albendazole consist of: oxygen Albendazole micropowder or hydrochloric acid oxygen Albendazole 20～100% (W/W), water soluble medical carrier material add to 100% (W/W); Also can add the local analgesia agent in the preparation; (2), the described liquid preparation that contains oxygen Albendazole or hydrochloric acid oxygen Albendazole consists of: oxygen Albendazole micropowder or hydrochloric acid oxygen Albendazole 5～30% (W/V), liquid dispersion medium add to 100% (V/V); Also can add the local analgesia agent in the preparation; (3), the described solid preparation that contains Avermectins medicine consists of: Avermectins medicine 1～50% (W/W), water soluble medical carrier material add to 100% (W/W); Also can add local analgesia agent, antioxidant in the preparation; (4), the described liquid preparation that contains Avermectins medicine consists of: Avermectins medicine 0.1～15% (W/V), liquid dispersion medium add to 100% (V/V); Also can add local analgesia agent, non-ionic surface active agent, suspending agent or slow releasing carrier material, antioxidant in the preparation.
Described water soluble medical carrier material comprises: saccharide, sugar alcohols, dextrin, cyclodextrin and derivant thereof, water soluble starch, the water soluble starch derivant is (as Oxytarch, crosslinked starch, phosphate ester starch, hydroxyalkyl starch, carboxymethyl starch, acetas starch, cationic starch, graft copolymerization starch, denaturated starch by acid, starch xanthate), the water-soluble cellulose ether class, molecular weight is greater than 1000 Polyethylene Glycol, polyvinylpyrrolidone, polyvinyl alcohol, polyacrylamide, acrylic acid and methacrylate polymer, polyethylene glycol oxide, poly, lignosulfonates, xanthan gum, but they more than one use together;
Described liquid dispersion medium comprises: water, 1,2-propylene glycol, glycerol, formal glycerine, molecular weight are less than 600 Polyethylene Glycol, but they more than one use together, also can add the dimethyl acetylamide or the N-methyl-ketopyrrolidine of 5～30% (V/V); Glyceryl triacetate, benzyl benzoate, they can be with 1, and 2-propylene glycol or formal glycerine use together; Ethyl oleate, suffering-capric acid triglyceride, vegetable oil;
Described ionic surfactant pack is drawn together: anhydrate condensation substance Brijs, Peregal P aregal, polyoxyethylene nonylphenol ether, polyoxyethylene castor oil condensation substance, polyoxyethylene hydrogenated Oleum Ricini condensation substance, the pluronic Pluronic of condensation substance Myrjs, polyoxyethylene and high fatty alcohol of sorbitol higher fatty acids ester condensates Tween, polyoxyethylene higher fatty acids of fatty acid glyceride, polyglyceryl fatty acid ester, sucrose ester, the sorbitol high-grade aliphatic ester Span that anhydrates, polyoxyethylene;
Described local analgesia agent comprises: chlorobutanol, benzyl alcohol, procaine hydrochloride, lidocaine hydrochloride, tetracaine hydrochloride;
Described suspending agent or slow releasing carrier material comprise:, water-soluble cellulose ether class, molecular weight be greater than 1000 Polyethylene Glycol, polyvinylpyrrolidone, polyvinyl alcohol, xanthan gum, but they more than one use together;
Described antioxidant comprises: sodium thiosulfate, thiourea, dibutyl phenyl methylcarbamate, to hydroxyl tert-butyl group methoxybenzene, propyl gallate;
Select following example to further specify and use the preparation composition with and use method with:
(1) composition of preparation A and preparation B and use method with:
Preparation A: hydrochloric albendazole sulfoxide 100% (W/W);
Preparation B: Avermectins medicine 2.85% (W/V), Polyethylene Glycol 8000-100006～10% (W/V) or polyvinylpyrrolidone 3～10% (W/V), chlorobutanol 0.7% (W/V), water for injection to 100% (V/V).
Using method: during use preparation A is mixed with preparation B, shake up, be prepared into the molten suspension of hydrochloric albendazole sulfoxide 5～30% (W/V); This molten suspension is used for the animal parasitosis control, subcutaneous injection, and dosage is: Albendazole oxide monohydrochloride 2.5～20mg/kg b.w.; Avermectins medicine 0.166～1.4mg/kgb.w..
(2) composition of preparation A and formulation C and use method with:
Preparation A: hydrochloric albendazole sulfoxide 100% (W/W);
Formulation C: the liquid preparation (microemulsion or Emulsion or solution type preparation or suspension) that contains 0.4% Avermectins medicine;
Using method: with preparation A and the formulation C mixed by 1: 9 (W/V), be prepared into solution or suspension, be used for the animal parasitosis control, per os gavages administration, and using dosage is: 6～18 kg body weight gavage this suspension or solution 1ml.
(3) composition of preparation A and preparation D and use method with:
Preparation A: hydrochloric albendazole sulfoxide 100% (W/W);
Preparation D: Avermectins medicine 6% (W/V), Polyethylene Glycol 8000-100006～10% (W/V) or polyvinylpyrrolidone 3～10% (W/V), chlorobutanol 0.7% (W/V), water for injection to 100% (V/V).
Using method: during use preparation A is mixed with preparation D, shake up, be prepared into the molten suspension of hydrochloric albendazole sulfoxide 30% (W/V); This molten suspension is used for the animal parasitosis control, subcutaneous injection, and dosage is: Albendazole oxide monohydrochloride 5～10mg/kg b.w.; Avermectins medicine 0.7～1.4mg/kg b.w..
(4) composition of preparation E and preparation F and use method with:
Preparation E: hydrochloric albendazole sulfoxide 50% (W/W), levamisole hydrochloride 50% (W/W);
Preparation F: Avermectins medicine 1.5% (W/V), chlorobutanol 0.8% (W/V), polyvinylpyrrolidone 7% (W/V), sodium carboxymethyl cellulose 0.2% (W/V), water for injection to 100% (V/V).
Using method: during use preparation E is mixed in 3: 7 ratio (W/V) with preparation F, shake up, be prepared into the molten suspension of hydrochloric albendazole sulfoxide 15% (W/V), levamisole hydrochloride 15% (W/V), Avermectins medicine 1.05% (W/V); This molten suspension is used for the animal parasitosis control, subcutaneous injection or oral administration, and dosage is: Albendazole oxide monohydrochloride 5～7.5mg/kg b.w.; Levamisole hydrochloride 5～7.5mg/kg b.w.; Avermectins medicine 0.35～0.525mg/kg b.w..
(5) composition of preparation G and preparation H and use method with:
Preparation G: the water-solubility carrier material to 100% (W/W) of hydrochloric albendazole sulfoxide 20～100% (W/W), solid state;
Preparation H: the water-solubility carrier material to 100% (W/W) of Avermectins medicine 1～30% (W/W), solid state;
Use method with: in 5～20: the ratio of 0.66～20 (weight ratio), get preparation G and preparation H, place container, add water, be prepared into the aqueous suspensions of hydrochloric albendazole sulfoxide 5～20% (W/V), Avermectins medicine 0.3～0.6% (W/V); This aqueous suspensions is used for animal parasitosis controls such as cattle, sheep, and per os gavages, and dosage is: Albendazole oxide monohydrochloride 5～20mg/kg b.w.; Avermectins medicine 0.2～0.6mg/kg b.w...
(6) composition of preparation A and preparation I and use method with:
Preparation A: the water-solubility carrier material to 100% (W/W) of hydrochloric albendazole sulfoxide 95～100% (W/W), solid state;
Preparation I: the water-solubility carrier material to 100% (W/W) of Avermectins medicine 2.15% (W/W), levamisole hydrochloride 70% (W/W), solid state;
Use method with: in the ratio of 5: 7 (weight ratio), get preparation A and preparation I, place container, add water, be prepared into the aqueous suspensions of hydrochloric albendazole sulfoxide 10% (W/V), levamisole hydrochloride 9.8% (W/V), Avermectins medicine 0.3% (W/V); This aqueous suspensions is used for animal parasitosis controls such as cattle, sheep, and per os gavages, and dosage is: Albendazole oxide monohydrochloride 10mg/kg b.w.; Avermectins medicine 0.3mg/kg b.w.; Levamisole hydrochloride 9.8mg/kg b.w..
(7) composition of preparation J and preparation L and use method with:
Preparation J: Albendazole oxide monohydrochloride 14% (W/V), water or 1,2-propylene glycol or 1,2-propylene glycol/formal glycerine to 100% (V/V);
Preparation L: Avermectins medicine 15% (W/V), formal glycerine 30% (V/V), benzyl alcohol 20% (V/V), polyvinylpyrrolidone 3～5% (W/V), 1,2-propylene glycol to 100% (V/V);
Use method with: in the ratio of 95: 5 (volume ratio), get preparation J and preparation M, place container, be prepared into the solution of hydrochloric albendazole sulfoxide 13.3% (W/V), Avermectins medicine 0.75% (W/V); This solution is used for animal parasitosis controls such as cattle, sheep, subcutaneous injection, and dosage is: Albendazole oxide monohydrochloride 6.65mg/kg b.w.; Avermectins medicine 0.375mg/kg b.w..
(8) composition of preparation J and preparation M and use method with:
Preparation J: Albendazole oxide monohydrochloride 14% (W/V), water/1,2-propylene glycol to 100% (V/V);
Preparation M: Avermectins medicine 3.5% (W/W), cetomacrogol 1000 07% (V/V), benzyl alcohol 1% (V/V), water/glycerol (9: 1) are to 100% (V/V);
Use method with: in the ratio of 8: 2 (weight ratio), get preparation J and preparation M, place container, be prepared into the solution of hydrochloric albendazole sulfoxide 11.2% (W/V), Avermectins medicine 0.7% (W/V); This solution is used for animal parasitosis controls such as cattle, sheep, and per os gavages or subcutaneous injection, and during oral administration, dosage is: Albendazole oxide monohydrochloride 5.6mg/kg b.w.; Avermectins medicine 0.35mg/kg b.w.; During the subcutaneous injection administration, Albendazole oxide monohydrochloride 7.43mg/kg b.w.; Avermectins medicine 0.466mg/kgb.w..
The present invention lays particular emphasis on the combination of describing the preparation active ingredient and uses method with, and the preparation method of relevant solid preparation (as tablet, powder, granule) and liquid preparation all can prepare according to a conventional method.
The specific embodiment
With example preparation of the present invention is described below, but example do not limit the scope of the invention, scope of the present invention and core content are determined according to claims.
The compounding powder of example 1, hydrochloric albendazole sulfoxide and levamisole hydrochloride and the method for using with that contains the liquid preparation of ivermectin
The compounding powder of hydrochloric albendazole sulfoxide and levamisole hydrochloride is formed: a, Albendazole oxide monohydrochloride 30% (W/W), b, levamisole hydrochloride 30% (W/W), c, cane sugar powder 40% (W/W); The composition that contains the liquid preparation of ivermectin: a, ivermectin 0.45% (W/V), b, cetomacrogol 1000 07% (W/V), c, glycerol 20% (V/V), d, 1,2-propylene glycol 10% (V/V), e, water add to 100% (V/V); Using method: be used for cattle, the sick control of sheep parasite.During use, the compounding powder 30g of hydrochloric albendazole sulfoxide and levamisole hydrochloride is mixed with the liquid preparation 70ml that contains ivermectin, shake up.Using dosage is: 0.8～1.2ml/10kg b.w., oral administration.
The compound recipe injectable powder of example 2, hydrochloric albendazole sulfoxide and levamisole hydrochloride and the method for using with that contains the liquid infusion agent of drawing rhzomorph
The compound recipe injectable powder of hydrochloric albendazole sulfoxide and levamisole hydrochloride: a, Albendazole oxide monohydrochloride 50% (W/W), b, levamisole hydrochloride 50% (W/W); Contain the liquid infusion agent of drawing rhzomorph: a, road draw rhzomorph 4% (W/V), b, cetomacrogol 1000 07% (W/V), c, glycerol 15% (V/V), d, N-methyl-ketopyrrolidine/formal glycerine 15% (V/V), e, benzyl alcohol 1% (V/V), f, water add to 100% (V/V); Using method: be used for animal parasitosis controls such as cattle, sheep, pig.During use, with the compound recipe injectable powder 30g of hydrochloric albendazole sulfoxide and levamisole hydrochloride with contain the liquid infusion agent 70ml that draws rhzomorph and mix, shake up, through subcutaneous or intramuscular injection.Using dosage is 0.5～1ml/20kg b.w..
The compounding powder of example 3, hydrochloric oxygen Albendazole and levamisole hydrochloride and the method for using with that contains the liquid preparation of ivermectin
The compounding powder of hydrochloric oxygen Albendazole and levamisole hydrochloride: a, hydrochloric acid oxygen Albendazole micropowder 38.5% (W/W), b, levamisole hydrochloride micropowder 61.5% (W/W); The liquid preparation that contains ivermectin: a, ivermectin 0.9% (W/V), b, 1,2-propylene glycol add to 100% (V/V); Using method: be used for pig, cattle, the sick control of sheep parasite.During use, the compounding powder 30g of hydrochloric oxygen Albendazole and levamisole hydrochloride is mixed with the liquid preparation 70ml that contains ivermectin, shake up, oral administration, dosage is: 1ml/18～22kg b.w..
Example 4, contain the solid preparation of using with of anti-parasite medicine
Preparation is formed: preparation A tablet, and every heavy 0.5g contains and draws rhzomorph 0.2g; Preparation B tablet, every hydrochloric levamisole 0.7g, Albendazole oxide monohydrochloride 1g, the heavy 2.5g of sheet; Using method: be used for cattle, the sick control of sheep parasite.During use, quantitatively get 10 tablet preparation A and 50 tablet preparation B, add 0.4L water, make it to be uniformly dispersed, with continuous medicine-filling device oral administration, dosage is 0.8～1.2ml/10kgb.w..
Example 5, contain the solid preparation of using with of anti-parasite medicine
Preparation is formed: preparation A tablet, and every heavy 0.5g contains ivermectin 0.2g, and all the other are the water-solubility carrier material; Preparation B powder, hydrochloric albendazole sulfoxide micropowder 90%; Usage: be used for cattle, the sick control of sheep parasite.During use, in the container of splendid attire 10 tablet preparation A, add water for injection 40ml, shake, be prepared into suspension, then this suspension is injected in the container that contains 11g preparation B, shakes and make the Albendazole oxide monohydrochloride dissolving, promptly get injection, the subcutaneous injection administration, dosage is: 0.8～1.4ml/40kg b.w..
Example 6, contain the solid preparation of using with of anti-parasite medicine
Preparation is formed: preparation A tablet, and the heavy 0.5g of sheet contains ivermectin 0.2g; Preparation B tablet, hydrochloric albendazole sulfoxide 1g/ sheet, the heavy 1.5g of sheet; Usage: be used for cattle, the sick control of sheep parasite.During use, quantitatively get 10 tablet preparation A and 50 tablet preparation B, add 0.4L water, make it to be uniformly dispersed, with continuous medicine-filling device oral administration, dosage is 0.8～1.2ml/10kg b.w..
Example 7, hydrochloric albendazole sulfoxide powder and contain the method for using with of the liquid preparation of ivermectin
(1), hydrochloric albendazole sulfoxide powder is formed: a, Albendazole oxide monohydrochloride 60% (W/W); B, glucose powder 40% (W/W); (2), the composition that contains the liquid preparation of ivermectin: a, ivermectin 0.45% (W/V); B, cetomacrogol 1000 07% (W/V); C, glycerol 10% (V/V); D, 1,2-propylene glycol 10% (V/V); E, water add to 100% (V/V); (3), usage: be used for cattle, the sick control of sheep parasite.During use, hydrochloric albendazole sulfoxide powder 15g is mixed with the liquid preparation 70ml that contains ivermectin, shake up.Using dosage is: 0.8～1.2ml/10kgb.w., oral administration.
The compound recipe injectable powder of example 8, hydrochloric albendazole sulfoxide and levamisole hydrochloride and the method for using with that contains the liquid infusion agent of drawing rhzomorph
(1), the compound recipe injectable powder of hydrochloric albendazole sulfoxide and levamisole hydrochloride: a, sour albendazole sulfoxide 50% (W/W); B, levamisole hydrochloride 50% (W/W); (2), contain the liquid infusion agent of drawing rhzomorph: a, road draw rhzomorph 4% (W/V); B, cetomacrogol 1000 07% (W/V); C, glycerol 15% (V/V); D, N-methyl-ketopyrrolidine/formal glycerine 15% (V/V); E, benzyl alcohol 1% (V/V); F, water add to 100% (V/V); (3), usage: be used for animal parasitosis controls such as cattle, sheep, pig.During use, with the compounding powder 30g of hydrochloric albendazole sulfoxide and levamisole hydrochloride with contain the liquid preparation 70ml that draws rhzomorph and mix, shake up, through subcutaneous or intramuscular injection.Using dosage is 0.5～1ml/20kg b.w..
Example 9, contain the solid preparation of using with of anti-parasite medicine
Preparation A tablet, every heavy 0.5g contains and draws rhzomorph 0.2g; Preparation B tablet, every hydrochloric albendazole sulfoxide 1g, the heavy 1.5g of sheet; Usage: be used for cattle, the sick control of sheep parasite.During use, quantitatively get 10 tablet preparation A and 50 tablet preparation B, add 0.4L water, make it to be uniformly dispersed, with continuous medicine-filling device oral administration, dosage is 0.8～1.2ml/10kg b.w..
Example 10, contain the solid preparation of using with of anti-parasite medicine
Preparation A tablet, every heavy 0.5g contains ivermectin 0.2g, and all the other are the water-solubility carrier material; Preparation B powder, hydrochloric albendazole sulfoxide micropowder 90%; Usage: be used for cattle, the sick control of sheep parasite.During use, in the container of splendid attire 10 tablet preparation A, add water for injection 40ml, shake, be prepared into suspension, then this suspension is injected in the container that contains 11g preparation B, shakes and make the Albendazole oxide monohydrochloride dissolving, promptly get injection, the subcutaneous injection administration, dosage is: 0.8～1.4ml/40kg b.w..
The mixture and the using method of example 11, Albendazole oxide monohydrochloride micropowder and 4% ivermectin solution composition
Preparation A: Albendazole oxide monohydrochloride micropowder 20～22g/ bottle (100ml volume); Preparation B: sterilized water 68ml/ bag; Formulation C: 20% ivermectin injection 20ml/ bottle consists of: ivermectin 20% (W/V), PVP10% (W/V), chlorobutanol 2% (W/V), dimethyl acetylamide 40～50% (V/V), 1, and the 2-propylene glycol adds to 100% (V/V); Using method: extract the 68ml sterilized water, be injected in the plastic bottle of the tool plug of adorning 20～22g Albendazole oxide monohydrochloride, shake, after making it most of dissolving, get 20ml formulation C (20% ivermectin solution), be injected in the solution of hydrochloric albendazole sulfoxide, finish, jolting immediately when liquid becomes to hang emulsus, can in time be used.Suggestion used up this mixture in 12 hours.With parasitic infection inside and outside this mixture control animal body, this agent of 30～60kg b.w. subcutaneous injection 0.8～1.2ml, the control phase reached more than 60 days.
Mixture and using method that example 12, Albendazole oxide monohydrochloride micropowder and 5% ivermectin suspension are formed
Preparation A: Albendazole oxide monohydrochloride micropowder 20～22g/ bottle (or bag); Preparation B: contain the suspension 85ml/ bag of ivermectin 5%, this agent consists of: ivermectin/castor oil hydrogenated (1: 1) solid dispersion microparticle 10% (W/V), PVP5% (W/V), dimethyl acetylamide 10% (V/V), chlorobutanol 0.5% (W/V), glycerol 5～30%, water add to 100% (V/V).Preparation method: ivermectin and PVP with dimethyl acetylamide dissolving back and the HCO mixing that has melted, in stirring condition has a down dip entry, are ground to less than 75 μ m afterwards, add glycerol and water to final volume promptly; Using method: during use, the plastic bag interface is cut off, connected No. 20 injection needles for animals, the 85ml suspension in the bag all is pressed in the container of dress Albendazole oxide monohydrochloride.Available ordinary syringe, also available continuous injector is given the animal subcutaneous injection, this agent of 30～50kg b.w. subcutaneous injection 1～1.5ml, control nematicide and ectozoic preventive effect phase can reach more than 60 days, also had the effect of killing distoma hepaticum and cestode simultaneously.
The method of using with of example 13,10% Albendazole oxide monohydrochloride solution and 5% ivermectin suspensoid
The preparation method of 5% ivermectin suspensoid is with example 12.During use, extract 5% ivermectin suspensoid earlier, extract 10% Albendazole oxide monohydrochloride aqueous solution again with syringe, every 20kg body weight cattle, sheep or pig, extract 5% ivermectin suspensoid 0.5ml with the 2ml syringe, extract 10% Albendazole oxide monohydrochloride solution 1ml again, subcutaneous injection.
Using with of example 14, Albendazole oxide monohydrochloride micropowder and 0.6% ivermectin micro emulsion
During use, with 0.6% ivermectin micro emulsion (ivermectin 0.6%, the dimethyl acetylamide 5%, 1 for preparing, 2-propylene glycol 15%, EL-40 8%, water add to 100%) 92ml, mix with 10g Albendazole oxide monohydrochloride micropowder, the animal per os of 20kg body weight gavages this mixture 1～2ml, available hand sprayer administration, or use the injector for medical purpose administration, also available continuous medicine-filling gavages, and also can be made into drinking agent and drink, and also can be mixed in the feedstuff and feed.
The method of using with of example 15,20% Albendazole oxide monohydrochloride liquid preparation and 2% ivermectin liquid preparation
Preparation A: contain 1 of 20% Albendazole oxide monohydrochloride, 2-propylene glycol/formal glycerine (1: 1) solution; Preparation B: the glycerol triacetate solution that contains ivermectin 2%; The method of using with has following three kinds: method 1: the connection tube of apparatus threeway is communicated with preparation A, preparation B and continuous injector, advances syringe piston, A, and two kinds of medicinal liquids of B can inject under the animal skins by equal-volume, 40kg body weight injection A+B liquid 2ml; Method 2: during use, preparation A is mixed with preparation B, 20kg body weight subcutaneous injection A+B mixed liquor 1ml, this mixture used up in 4 hours as far as possible; Method 3: during use, according to dosage earlier get preparation A, then get preparation B again, be used for the animal of 40kg body weight, get preparation A liquid and each 1ml of preparation B liquid successively, a subcutaneous injection with syringe.
The method of using with of example 16,20% Albendazole oxide monohydrochloride liquid preparation and 2% ivermectin liquid preparation
Preparation A: contain the formal glycerine solution or formal glycerine/1 of 20% Albendazole oxide monohydrochloride, 2-propylene glycol (2: 1) solution; Preparation B: the Benzyl Benzoate ester solution that contains ivermectin 2%; The method of using with has following three kinds: method 1: the connection tube of apparatus threeway is communicated with preparation A, preparation B and continuous injector, advances syringe piston, A, and two kinds of medicinal liquids of B can inject under the animal skins by equal-volume, 40kg body weight injection A+B liquid 2ml; Method 2: during use, preparation A is mixed with preparation B, 20kg body weight subcutaneous injection A+B mixed liquor 1ml, this mixture used up in 4 hours as far as possible; Method 3: during use, according to dosage earlier get preparation A, then get preparation B again, be used for the animal of 40kg body weight, get preparation A liquid and each 1ml of preparation B liquid successively, a subcutaneous injection with syringe.
The method of using with of example 17,20% Albendazole oxide monohydrochloride liquid preparation and 30% ivermectin liquid preparation
Preparation A: contain 1 of 20% Albendazole oxide monohydrochloride, 2-propylene glycol liquid or formal glycerine/1,2-propylene glycol (1: 2) liquid 95ml/ bottle; Preparation B: contain formal glycerine/benzyl alcohol (2: 1) solution of 30% ivermectin, every bottled amount is 5～5.5ml; Using method: during use, get 5ml preparation B and be injected among the 95ml preparation A mixing, getting mixture 5ml notes gets back in the B bottle, flushing, sucking-off is annotated and is got back in the A bottle again, must contain ivermectin 1.5% (W/V), Albendazole oxide monohydrochloride or oxfendazole chloride's 19% mixture.Be used for the animal parasitosis control, the 40kg body weight is injected this mixture 1ml.When not adding benzyl alcohol in preparation B, the mixture that makes up with preparation A still can orally use, and the 40kg body weight is injected this mixture 1ml.This mixture is stable within 10 hours, and this mixture is easy to use.
Example 18,1.15% ivermectin oral liquid and the combination of albendazole sulfoxide powder use mouth sprays with
With 1.15% ivermectin oral liquid 26ml, in the volumetrical hand sprayer of the 30～35ml that packs into; Albendazole oxide monohydrochloride is packed as the packing specification of 6g/ bag; During use, the 6g Albendazole oxide monohydrochloride is poured in 1.15% the ivermectin oral liquid (26ml), shakes to the major part dissolving, can be through the oral cavity spray delivery, 30～40 kg body weight are through oral cavity spray delivery 1ml.
The method of using with of example 19,0.5% ivermectin oral liquid and Albendazole oxide monohydrochloride powder
To contain ivermectin 0.5% oral liquid 90ml, be encased in the plastic solution device that can be communicated with the continuous medicine-filling device, during use, after adding 10～12g Albendazole oxide monohydrochloride is miscible, be communicated with drencher, mixture is injected the oral cavity dosage is: the animal of 15～20 kg body weight gavages this agent 1ml.
Claims (10)
1, a kind of method of using with of veterinary antiparasitic preparation, it is characterized in that the solid preparation that will contain Avermectins medicine mixes when in use with the solid preparation that contains oxygen Albendazole or hydrochloric acid oxygen Albendazole, convert water or water for injection or other liquid dispersion medium and be prepared into solution or molten suspension or suspension, be used for the animal parasitosis control, injection or oral administration, during drug administration by injection, dosage is: oxygen Albendazole or hydrochloric acid oxygen Albendazole 2.5～30mg/kg b.w.; Avermectins medicine 0.2～2mg/kg b.w.; During oral administration, dosage is: oxygen Albendazole or hydrochloric acid oxygen Albendazole 5～30mg/kg b.w.; Avermectins medicine 0.1～0.7mg/kg b.w..
2, a kind of method of using with of veterinary antiparasitic preparation, it is characterized in that the liquid preparation that will contain Avermectins medicine mixes when in use with the liquid preparation that contains oxygen Albendazole or hydrochloric acid oxygen Albendazole, be prepared into solution or molten suspension or suspension, be used for the animal parasitosis control, injection or oral administration, during drug administration by injection, dosage is: oxygen Albendazole or hydrochloric acid oxygen Albendazole 2.5～30mg/kg b.w.; Avermectins medicine 0.2～2mg/kg b.w.; During oral administration, dosage is: oxygen Albendazole or hydrochloric acid oxygen Albendazole 5～30mg/kg b.w.; Avermectins medicine 0.1～0.7mg/kg b.w..
3, a kind of method of using with of veterinary antiparasitic preparation, it is characterized in that the liquid preparation that will contain Avermectins medicine mixes when in use with the solid preparation that contains oxygen Albendazole or hydrochloric acid oxygen Albendazole, be prepared into solution or molten suspension or suspension, be used for the animal parasitosis control, injection or oral administration, during drug administration by injection, dosage is: oxygen Albendazole or hydrochloric acid oxygen Albendazole 2.5～30mg/kg b.w.; Avermectins medicine 0.2～2mg/kg b.w.; During oral administration, dosage is: oxygen Albendazole or hydrochloric acid oxygen Albendazole 5～30mg/kg b.w.; Avermectins medicine 0.1～0.7mg/kg b.w..
4, a kind of method of using with of veterinary antiparasitic preparation, it is characterized in that the solid preparation that will contain Avermectins medicine mixes when in use with the liquid preparation that contains oxygen Albendazole or hydrochloric acid oxygen Albendazole, be prepared into solution or molten suspension or suspension, be used for the animal parasitosis control, injection or oral administration, during drug administration by injection, dosage is: oxygen Albendazole or hydrochloric acid oxygen Albendazole 2.5～30mg/kg b.w.; Avermectins medicine 0.2～2mg/kg b.w.; During oral administration, dosage is: oxygen Albendazole or hydrochloric acid oxygen Albendazole 5～30mg/kg b.w.; Avermectins medicine 0.1～0.7mg/kg b.w..
5, by the described preparation of claim 1-4, it is characterized in that in the described solid preparation that contains Avermectins medicine, also can adding the levamisole hydrochloride of 20～70% (W/W), or in containing the liquid preparation of Avermectins medicine, add the levamisole hydrochloride of 5～20% (W/V); When being used for the animal parasitosis control, the levamisole hydrochloride using dosage is 5～15mg/kg b.w..
6, by the described preparation of claim 1-4, it is characterized in that in the described solid preparation that contains the oxygen Albendazole, also can adding the levamisole hydrochloride of 20～60% (W/W), or in the liquid preparation that contains the oxygen Albendazole, add the levamisole hydrochloride of 5～20% (W/V); When being used for the animal parasitosis control, the levamisole hydrochloride using dosage is 5～15mg/kg b.w..
7, by the described preparation of claim 1-4, it is characterized in that: (1) described solid preparation that contains oxygen Albendazole or hydrochloric acid oxygen Albendazole consists of: oxygen Albendazole micropowder or hydrochloric acid oxygen Albendazole 20～100% (W/W), water soluble medical carrier material add to 100% (W/W); Also can add the local analgesia agent in the preparation; (2) the described liquid preparation that contains oxygen Albendazole or hydrochloric acid oxygen Albendazole consists of: oxygen Albendazole micropowder or hydrochloric acid oxygen Albendazole 5～30% (W/V), liquid dispersion medium add to 100% (V/V); Also can add the local analgesia agent in the preparation; (3) the described solid preparation that contains Avermectins medicine consists of: Avermectins medicine 1～50% (W/W), water soluble medical carrier material add to 100% (W/W); Also can add local analgesia agent, antioxidant in the preparation; (4) the described liquid preparation that contains Avermectins medicine consists of: Avermectins medicine 0.1～15% (W/V), liquid dispersion medium add to 100% (V/V); Also can add local analgesia agent, non-ionic surface active agent, suspending agent or slow releasing carrier material, antioxidant in the preparation.
8, described by claim 7, it is characterized in that: (1) described water soluble medical carrier material comprises: saccharide, sugar alcohols, dextrin, cyclodextrin and derivant thereof, water soluble starch, the water soluble starch derivant is (as Oxytarch, crosslinked starch, phosphate ester starch, hydroxyalkyl starch, carboxymethyl starch, acetas starch, cationic starch, graft copolymerization starch, denaturated starch by acid, starch xanthate), the water-soluble cellulose ether class, molecular weight is greater than 1000 Polyethylene Glycol, polyvinylpyrrolidone, polyvinyl alcohol, polyacrylamide, the acrylic or methacrylic acid polymer, polyethylene glycol oxide, poly, lignosulfonates, xanthan gum, but they more than one use together; (2) described liquid dispersion medium comprises: water, 1,2-propylene glycol, glycerol, formal glycerine, molecular weight are less than 600 Polyethylene Glycol, but they more than one use together, also can add the dimethyl acetylamide or the N-methyl-ketopyrrolidine of 5～30% (V/V); Glyceryl triacetate, benzyl benzoate, they can be with 1, and 2-propylene glycol or formal glycerine use together; Ethyl oleate, suffering-last of the ten Heavenly stems triglyceride, vegetable oil; (3) described ionic surfactant pack is drawn together: anhydrate condensation substance Brijs, Peregal P aregal, polyoxyethylene nonylphenol ether, polyoxyethylene castor oil condensation substance, polyoxyethylene hydrogenated Oleum Ricini condensation substance, the pluronic Pluronic of condensation substance Myrjs, polyoxyethylene and high fatty alcohol of sorbitol higher fatty acids ester condensates Tween, polyoxyethylene higher fatty acids of fatty acid glyceride, polyglyceryl fatty acid ester, sucrose ester, the sorbitol high-grade aliphatic ester Span that anhydrates, polyoxyethylene; (4) described local analgesia agent comprises: chlorobutanol, benzyl alcohol, procaine hydrochloride, lidocaine hydrochloride, tetracaine hydrochloride; (5) described suspending agent or slow releasing carrier material comprise:, water-soluble cellulose ether class, molecular weight be greater than 1000 Polyethylene Glycol, polyvinylpyrrolidone, polyvinyl alcohol, xanthan gum, but they more than one use together; (6) described antioxidant comprises: sodium thiosulfate, thiourea, dibutyl phenyl methylcarbamate, to hydroxyl tert-butyl group methoxybenzene, propyl gallate;
9, described by claim 1-8, it is as follows to it is characterized in that using with preparation composition and using method:
(1) composition of preparation A and preparation B and use method with:
Preparation A: hydrochloric albendazole sulfoxide 95～100% (W/W);
Preparation B: Avermectins medicine 2.85% (W/V), Polyethylene Glycol 8000-10000 6～10% (W/V) or polyvinylpyrrolidone 3～10% (W/V), chlorobutanol 0.7% (W/V), water for injection to 100% (V/V).
Using method: during use preparation A is mixed with preparation B, shake up, be prepared into the molten suspension of hydrochloric albendazole sulfoxide 5～30% (W/V); This molten suspension is used for the animal parasitosis control, subcutaneous injection, and dosage is: Albendazole oxide monohydrochloride 2.5～20mg/kg b.w.; Avermectins medicine 0.166～1.4mg/kgb.w..
(2) composition of preparation A and formulation C and use method with:
Preparation A: hydrochloric albendazole sulfoxide 95～100% (W/W);
Formulation C: the liquid preparation (microemulsion or Emulsion or solution type preparation or suspension) that contains 0.4% Avermectins medicine;
Using method: with preparation A and the formulation C mixed by 1: 9 (W/V), be prepared into solution or suspension, be used for the animal parasitosis control, per os gavages administration, and using dosage is: 6～18 kg body weight gavage this suspension or solution 1ml.
(3) composition of preparation A and preparation D and use method with:
Preparation A: hydrochloric albendazole sulfoxide 95～100% (W/W);
Preparation D: Avermectins medicine 6% (W/V), Polyethylene Glycol 8000-10000 6～10% (W/V) or polyvinylpyrrolidone 3～10% (W/V), chlorobutanol 0.7% (W/V), water for injection to 100% (V/V).
Using method: during use preparation A is mixed with preparation D, shake up, be prepared into the molten suspension of hydrochloric albendazole sulfoxide 15～30% (W/V); This molten suspension is used for the animal parasitosis control, subcutaneous injection, and dosage is: Albendazole oxide monohydrochloride 5～10mg/kg b.w.; Avermectins medicine 0.7～1.4mg/kg b.w..
(4) composition of preparation E and preparation F and use method with:
Preparation E: hydrochloric albendazole sulfoxide 50% (W/W), levamisole hydrochloride 50% (W/W);
Preparation F: Avermectins medicine 1.5% (W/V), chlorobutanol 0.8% (W/V), polyvinylpyrrolidone 7% (W/V), sodium carboxymethyl cellulose 0.2% (W/V), water for injection to 100% (V/V).
Using method: during use preparation E is mixed in 3: 7 ratio (W/V) with preparation F, shake up, be prepared into the molten suspension of hydrochloric albendazole sulfoxide 15% (W/V), levamisole hydrochloride 15% (W/V), Avermectins medicine 1.05% (W/V); This molten suspension is used for the animal parasitosis control, subcutaneous injection or oral administration, and dosage is: Albendazole oxide monohydrochloride 5～7.5mg/kg b.w.; Levamisole hydrochloride 5～7.5mg/kg b.w.; Avermectins medicine 0.35～0.525mg/kg b.w..
(5) composition of preparation G and preparation H and use method with:
Preparation G: the water-solubility carrier material to 100% (W/W) of hydrochloric albendazole sulfoxide 20～100% (W/W), solid state;
Preparation H: the water-solubility carrier material to 100% (W/W) of Avermectins medicine 1～30% (W/W), solid state;
Use method with: in 5～20: the ratio of 0.66～20 (weight ratio), get preparation G and preparation H, place container, add water, be prepared into the aqueous suspensions of hydrochloric albendazole sulfoxide 5～20% (W/V), Avermectins medicine 0.3～0.6% (W/V); This aqueous suspensions is used for animal parasitosis controls such as cattle, sheep, and per os gavages, and dosage is: Albendazole oxide monohydrochloride 5～20mg/kg b.w.; Avermectins medicine 0.2～0.6mg/kg b.w...
(6) composition of preparation A and preparation I and use method with:
Preparation A: the water-solubility carrier material to 100% (W/W) of hydrochloric albendazole sulfoxide 95～100% (W/W), solid state;
Preparation I: the water-solubility carrier material to 100% (W/W) of Avermectins medicine 2.15% (W/W), levamisole hydrochloride 70% (W/W), solid state;
Use method with: in the ratio of 5: 7 (weight ratio), get preparation A and preparation I, place container, add water, be prepared into the aqueous suspensions of hydrochloric albendazole sulfoxide 10% (W/V), levamisole hydrochloride 9.8% (W/V), Avermectins medicine 0.3% (W/V): this aqueous suspensions is used for animal parasitosis controls such as cattle, sheep, per os gavages, and dosage is: Albendazole oxide monohydrochloride 10mg/kg b.w.; Avermectins medicine 0.3mg/kg b.w.: levamisole hydrochloride 9.8mg/kg b.w..
(7) composition of preparation J and preparation L and use method with:
Preparation J: Albendazole oxide monohydrochloride 14% (W/V), water or 1,2-propylene glycol or 1,2-propylene glycol/formal glycerine to 100% (V/V);
Preparation L: Avermectins medicine 15% (W/V), formal glycerine 30% (V/V), benzyl alcohol 20% (V/V), polyvinylpyrrolidone 3～5% (W/V), 1,2-propylene glycol to 100% (V/V);
Use method with: in the ratio of 95: 5 (volume ratio), get preparation J and preparation L, place container, be prepared into the solution of hydrochloric albendazole sulfoxide 13.3% (W/V), Avermectins medicine 0.75% (W/V); This solution is used for animal parasitosis controls such as cattle, sheep, subcutaneous injection, and dosage is: Albendazole oxide monohydrochloride 6.65mg/kg b.w.; Avermectins medicine 0.375mg/kg b.w..
(8) composition of preparation J and preparation M and use method with:
Preparation J: Albendazole oxide monohydrochloride 14% (W/V), water/1,2-propylene glycol to 100% (V/V);
Preparation M: Avermectins medicine 3.5% (W/W), cetomacrogol 1000 0 7% (V/V), water/glycerol (9: 1) are to 100% (V/V);
Use method with: in the ratio of 8: 2 (weight ratio), get preparation J and preparation M, place container, be prepared into the solution of hydrochloric albendazole sulfoxide 11.2% (W/V), Avermectins medicine 0.7% (W/V); This solution is used for animal parasitosis controls such as cattle, sheep, and per os gavages or subcutaneous injection, and during oral administration, dosage is: Albendazole oxide monohydrochloride 5.6mg/kg b.w.; Avermectins medicine 0.35mg/kg b.w.; During the subcutaneous injection administration, dosage is: Albendazole oxide monohydrochloride 7.43mg/kg b.w.; Avermectins medicine 0.466mg/kg b.w..
10, described by claim 1-9, it is characterized in that described Avermectins medicine comprises: avilamycin abamectin, ivermectin ivermectin, 4"-Deoxy-4"-epi-methylaminoavermectin B1 emamectin, Ai Purui rhzomorph eprinomectin, road draw rhzomorph doramectin, moxidectin moxidectin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410037954 CN1698636A (en) | 2004-05-17 | 2004-05-17 | Mixing method of antiparasitic preparation for animals |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410037954 CN1698636A (en) | 2004-05-17 | 2004-05-17 | Mixing method of antiparasitic preparation for animals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1698636A true CN1698636A (en) | 2005-11-23 |
Family
ID=35474988
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410037954 Pending CN1698636A (en) | 2004-05-17 | 2004-05-17 | Mixing method of antiparasitic preparation for animals |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1698636A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008075984A3 (en) * | 2006-12-21 | 2008-07-31 | Bomac Research Ltd | Tablet formulation including macrocyclic lactone and levamisole anthelmintic agents |
| WO2008072985A3 (en) * | 2006-12-13 | 2008-08-28 | Bomac Research Ltd | Pour on formulation |
| CN104688680A (en) * | 2006-11-07 | 2015-06-10 | 贝林格尔·英格海姆维特梅迪卡有限公司 | Liquid preparation comprising a complex of pimobendan and cyclodextrin |
| CN106806363A (en) * | 2017-02-08 | 2017-06-09 | 北京中农华威生物医药研究院 | The paste of the anti-parasite medicine of class containing ivermectin |
| CN108432702A (en) * | 2018-04-09 | 2018-08-24 | 黄瑛 | A kind of administering method of the disease prevention of free-ranging chicken |
-
2004
- 2004-05-17 CN CN 200410037954 patent/CN1698636A/en active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104688680A (en) * | 2006-11-07 | 2015-06-10 | 贝林格尔·英格海姆维特梅迪卡有限公司 | Liquid preparation comprising a complex of pimobendan and cyclodextrin |
| WO2008072985A3 (en) * | 2006-12-13 | 2008-08-28 | Bomac Research Ltd | Pour on formulation |
| WO2008075984A3 (en) * | 2006-12-21 | 2008-07-31 | Bomac Research Ltd | Tablet formulation including macrocyclic lactone and levamisole anthelmintic agents |
| CN106806363A (en) * | 2017-02-08 | 2017-06-09 | 北京中农华威生物医药研究院 | The paste of the anti-parasite medicine of class containing ivermectin |
| CN106806363B (en) * | 2017-02-08 | 2019-04-12 | 中农华威生物制药(湖北)有限公司 | The paste of the anti-parasite medicine of class containing ivermectin |
| CN108432702A (en) * | 2018-04-09 | 2018-08-24 | 黄瑛 | A kind of administering method of the disease prevention of free-ranging chicken |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1283990A (en) | Long cating injectable formulations contg. hydrogenated castor oil | |
| JP2011105765A (en) | Surface parasiticide formulation and method of treatment | |
| CN101854926A (en) | Endoparasiticide composition for topical use | |
| CN1316900A (en) | Long time drug-sustained release preparation | |
| CA2737102C (en) | Benzimidazole anthelmintic compositions | |
| CN1275589C (en) | Slow releasing injection contg. antiparasitic medicine | |
| CN1698636A (en) | Mixing method of antiparasitic preparation for animals | |
| JP5342239B2 (en) | Benzidiimidazole non-aqueous composition | |
| CN1822880B (en) | Parasiticidal composition | |
| CN1572302A (en) | Application of avermectin containing parasite resistant pharmaceutical solid dispersion | |
| CN1170523C (en) | Sustained release pharmaceutical formulation for implantation | |
| CN1256948C (en) | Avermectin containing parasite resisitant long-acting injectio | |
| CN104095812B (en) | The preparation method of the emulsifiable oily injection containing Avermectins medicine | |
| EP1940396B1 (en) | Anthelmintic formulations | |
| CN1582925A (en) | Powder injection of benzimidazole hydrochloride, etc. for animals | |
| CN1490009A (en) | Sustained release injection containing medicine against coccindian | |
| AU2007221747B2 (en) | Medicament | |
| CN1376467A (en) | Veterinary medicine containing oxfendazole | |
| AU2003275779B2 (en) | Topical parasiticide formulations and methods of treatment | |
| WO2024162210A1 (en) | Self-emulsifying composition and production method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |